Acute Sensorineural Hearing Loss - Pipeline Review, H2 2016 - Global Markets Direct - Market Research

Acute Sensorineural Hearing Loss - Pipeline Review, H2 2016

Acute Sensorineural Hearing Loss - Pipeline Review, H2 2016 - Global Markets Direct - Market Research
Acute Sensorineural Hearing Loss - Pipeline Review, H2 2016
Published Jul 20, 2016
48 pages — Published Jul 20, 2016
Price US$ 2,000.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, Acute Sensorineural Hearing Loss - Pipeline Review, H2 2016, provides an overview of the Acute Sensorineural Hearing Loss pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Acute Sensorineural Hearing Loss, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Acute Sensorineural Hearing Loss and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Acute Sensorineural Hearing Loss
- The report reviews pipeline therapeutics for Acute Sensorineural Hearing Loss by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Acute Sensorineural Hearing Loss therapeutics and enlists all their major and minor projects
- The report assesses Acute Sensorineural Hearing Loss therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Acute Sensorineural Hearing Loss

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Acute Sensorineural Hearing Loss
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline

  
Source:
Document ID
GMDHC8249IDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents23
  List of Tables41
  List of Figures41
Introduction51
  Global Markets Direct Report Coverage51
Acute Sensorineural Hearing Loss Overview61
Therapeutics Development71
  Pipeline Products for Acute Sensorineural Hearing Loss Overview71
Acute Sensorineural Hearing Loss Therapeutics under Development by Companies81
Acute Sensorineural Hearing Loss Pipeline Products Glance93
  Late Stage Products91
  Clinical Stage Products101
  Early Stage Products111
Acute Sensorineural Hearing Loss Products under Development by Companies121
Acute Sensorineural Hearing Loss Companies Involved in Therapeutics Development135
  Nordmark Arzneimittel GmbH &Co. KG131
  Orbis Biosciences Inc141
  Otologic Pharmaceutics, Inc.151
  Pragma Therapeutics161
  Xigen SA171
Acute Sensorineural Hearing Loss Therapeutics Assessment1810
  Assessment by Monotherapy Products181
  Assessment by Combination Products191
  Assessment by Target202
  Assessment by Mechanism of Action222
  Assessment by Route of Administration242
  Assessment by Molecule Type262
Drug Profiles2814
  (acetylcysteine + disufenton sodium) Drug Profile281
  ancrod Drug Profile292
  betamethasone valerate ER Drug Profile311
  OR-102 Drug Profile321
  Otopotin Drug Profile331
  Otostem Drug Profile341
  Small Molecules for Sensorineural Hearing Loss Drug Profile351
  Small Molecules to Agonize mGlu7 for Acute Sensorineural Hearing Loss Drug Profile361
  Small Molecules to Inhibit Gamma Secretase for Sensorineural Hearing Loss Drug Profile371
  XG-102 Drug Profile384
Acute Sensorineural Hearing Loss Dormant Projects421
Acute Sensorineural Hearing Loss Product Development Milestones434
  Featured News &Press Releases431
    Jun 17, 2016: Auris Medical Initiates ASSENT Phase 3 Trial of AM-111 for Treatment of Sudden Deafness431
    Nov 13, 2015: Auris Medical Announces Enrollment of First Patient in HEALOS Study of AM-111 in Treatment of Idiopathic Sudden Sensorineural Hearing Loss431
    Jun 25, 2015: Auris Medical and Cochlear to Collaborate on Clinical Trial with AM-111 for Otoprotection during Cochlear Implant Surgery441
    May 04, 2015: Auris Medical Provides Update on Clinical Development Plan for AM-111441
    Nov 19, 2014: Otologic Pharmaceutics Initiates Phase 1 Clinical Study of NHPN-1010 for Hearing Disorders451
    Nov 13, 2012: Auris Medical Announces Positive Results From Phase IIb Trial With AM-111 For Treatment Of Acute Sensorineural Hearing Loss461
    Apr 20, 2012: Auris Medical Completes Enrolment In Phase IIb Trial With AM-111 For Treatment Of Acute Sensorineural Hearing Loss461
Appendix472
  Methodology471
  Coverage471
  Secondary Research471
  Primary Research471
  Expert Panel Validation471
  Contact Us471
  Disclaimer481

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Acute Sensorineural Hearing Loss - Pipeline Review, H2 2016" Jul 20, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Acute-Sensorineural-Hearing-Loss-Pipeline-Review-H2-2016-2088-16223>
  
APA:
Global Markets Direct - Market Research. (2016). Acute Sensorineural Hearing Loss - Pipeline Review, H2 2016 Jul 20, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Acute-Sensorineural-Hearing-Loss-Pipeline-Review-H2-2016-2088-16223>
  
US$ 2,000.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.